Efficacy questions are expected to dominate when a US FDA advisory committee convenes Feb. 14 to consider whether labeling for Pacira Pharmaceuticals Inc.'s Exparel (bupivacaine) should be expanded to include use as a nerve block and, if so, the specificity of any new claim for the local anesthetic.
At a Feb. 14 meeting, the Anesthetic and Analgesic Drug Products Advisory Committee will discuss Pacira's supplemental new drug application...